Recent Posts
Connect with:
Friday / August 19.
HomeminewsLucentis Positive Data

Lucentis Positive Data

Novartis has announced that data on Lucentis presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) highlights the benefit of individualised treatment and the drug’s long-term efficacy and safety profile in patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).[/vc_column_text][/vc_column]

In the RESTORE extension study, 240 patients suffering from DME received individualised treatment with Lucentis. Results demonstrated that to maintain mean visual acuity gained in the core study, an average of 3.7 injections and 2.7 injections were required in the second and third years, respectively. It was noted that in the core RESTORE study, patients showed vision gains with an average of seven injections for a one-year period.

In a separate study, 316 wet AMD patients received individualised treatment with Lucentis, as needed, according to a disease-activity-guided monitoring and treatment algorithm. At the end of three years, vision gains similar to pivotal phase III trials MARINA and ANCHOR were observed. Results showed that an average of 16 injections was required during three years, which was less than the regimen used in pivotal phase III studies.

Lucentis is currently approved for wet AMD, visual impairment due to DME and visual impairment due to macular edema following retinal vein occlusion.


By agreeing & continuing, you are declaring that you are a registered Healthcare professional with an appropriate registration. In order to view some areas of this website you will need to register and login.
If you are not a Healthcare professional do not continue.